This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azoulay-Dupuis, E.
Right arrow Articles by Bédos, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azoulay-Dupuis, E.
Right arrow Articles by Bédos, J. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2004, p. 80-85, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.80-85.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Efficacy of BB-83698, a Novel Peptide Deformylase Inhibitor, in a Mouse Model of Pneumococcal Pneumonia

E. Azoulay-Dupuis,* J. Mohler, and J. P. Bédos

INSERM, EMI-9933, Faculté de Médecine Xavier Bichat, Paris, France

Received 27 March 2003/ Returned for modification 8 July 2003/ Accepted 6 October 2003

The efficacy of BB-83698, a novel potent peptide deformylase inhibitor, was evaluated in a mouse model of acute pneumonia. The Streptococcus pneumoniae isolates tested included four virulent strains (one penicillin-susceptible wild-type strain, one macrolide-resistant strain, and two quinolone-resistant mutants [a mutant carrying mutations in ParC and GyrA and an efflux mutant] isogenic to the wild type) and two poorly virulent penicillin-resistant strains. Pneumonia was induced by intratracheal inoculation of 105 CFU (virulent strains) into immunocompetent mice or 107 CFU (less virulent strains) into leukopenic mice. Animals received three or six subcutaneous injections of antibiotics at 12- or 24-h intervals, with antibiotic treatment initiated at 3, 6, 12, or 18 h postinfection (p.i.). BB-83698 showed potent in vitro activity against all strains (MICs, 0.06 to 0.25 µg/ml). In the in vivo model, all control animals died within 2 to 5 days of infection. BB-83698 (80 mg/kg of body weight twice daily or 160 mg/kg once daily) protected 70 to 100% of the animals, as measured 10 days p.i., regardless of the preexisting resistance mechanisms. In contrast, the survival rates for animals treated with the comparator antibiotics were 30% for animals treated with erythromycin (100 mg/kg) and infected with the macrolide-resistant strain, 34% for animals treated with amoxicillin (200 mg/kg every 8 h) and infected with the penicillin-resistant strain, and 0 and 78% for animals treated with ciprofloxacin (250 mg/kg) and infected with the ParC and GyrA mutant and the efflux mutant, respectively. At 80 mg/kg, BB-83698 generated a peak concentration in lung tissue of 61.9 µg/ml within 1 h and areas under the concentration-times curves of 57.4 and 229.4 µg · h/ml for plasma and lung tissue, respectively. The emergence of S. pneumoniae isolates with reduced susceptibilities to BB-83698 was not observed following treatment with a suboptimal dosing regimen. In conclusion, the potent in vitro activity of BB-83698 against S. pneumoniae, including resistant strains, translates into good in vivo efficacy in a mouse pneumonia model.

* Corresponding author. Mailing address: INSERM EMI-9933, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France. Phone: (33) 1 44 85 61 53. Fax: (33) 1 44 85 61 47. E-mail: eazoulay{at}bichat.inserm.fr.

Antimicrobial Agents and Chemotherapy, January 2004, p. 80-85, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.80-85.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Osborne, C. S., Neckermann, G., Fischer, E., Pecanka, R., Yu, D., Manni, K., Goldovitz, J., Amaral, K., Dzink-Fox, J., Ryder, N. S. (2009). In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models. Antimicrob. Agents Chemother. 53: 3777-3781 [Abstract] [Full Text]  
  • Abgueguen, P., Azoulay-Dupuis, E., Noel, V., Moine, P., Rieux, V., Fantin, B., Bedos, J.-P. (2007). Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics. Antimicrob. Agents Chemother. 51: 208-214 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Mohler, J., Bedos, J. P., Barau, C., Fantin, B. (2006). Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.. Antimicrob. Agents Chemother. 50: 3033-3038 [Abstract] [Full Text]  
  • Ramanathan-Girish, S., McColm, J., Clements, J. M., Taupin, P., Barrowcliffe, S., Hevizi, J., Safrin, S., Moore, C., Patou, G., Moser, H., Gadd, A., Hoch, U., Jiang, V., Lofland, D., Johnson, K. W. (2004). Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor. Antimicrob. Agents Chemother. 48: 4835-4842 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»